Developer docs
API playgroundTry for free, no card

Search company profiles

Formic Ventures

Full company profile

uuid0007fub

Namestring
Formic Ventures
Legal namestring
Formic Ventures
Websiteurl
formic.vc
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Formic Ventures is a privately held, founder-financed venture capital firm based in San Francisco, California. Founded by Michael Antonov — co-founder and former Chief Software Architect of Oculus (acquired by Facebook in 2014) and co-founder of Scaleform (sold to Autodesk) — the firm makes seed-stage and early-stage equity investments in two principal verticals: biotechnology startups focused on human longevity and healthspan extension, and technology startups positioned as high-potential platforms in AI, robotics, and adjacent frontier sectors.

The firm's investment offering is its capital allocation, strategic guidance, and the network access of its small team. The internal team comprises Michael Antonov (Founder), Matt Shlosberg (Chief of Staff), Hayk Danielyan (Portfolio Manager, CFA Charterholder), and Maria Konovalenko (Scientist in Residence, PhD in Biology of Aging from the University of Southern California). Notable portfolio companies include Insilico Medicine, Schrodinger, Turn Bio, Anduril, Arctoris, Bolt, Zero, BEV, Iron Ox, and Volumetric, collectively numbering over 40 investments across biotech, AI, robotics, longevity, and consumer verticals.

Formic Ventures generates returns through equity appreciation in portfolio company exits (IPOs and acquisitions) and, where applicable, management fees and carried interest on committed capital. The firm is not disclosed to have institutional LP backing and operates as an independent, founder-owned investment vehicle. It is supported by an affiliated nonprofit, The Michael Antonov Foundation, which makes grants to 501(c)(3) organizations conducting human longevity-centered research. Co-investor relationships are maintained with LVF, Gigafund, and Anorak.

Short descriptiontext

Formic Ventures is a privately held, founder-financed seed-stage venture capital firm based in San Francisco that invests in biotechnology startups focused on human longevity and in technology startups across AI, robotics, and frontier sectors. It was founded by Oculus co-founder Michael Antonov and operates with a small specialized team.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, seed stage investments, biotechnology investments, longevity research funding, early-stage tech investments
Industry1 code
PRIMARYFSANAAAH
Venture Studios / Company Builders
NAICS code2 codes
  • Other Investment Pools and Funds5259
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles2 records
Revenue model1 record
1Venture Capital Returns
TypeLicensing Royalties
Description

Formic Ventures generates returns through equity investments in early-stage startups. As a VC firm, the primary revenue stream comes from capital gains on successful portfolio company exits via IPOs or acquisitions, supplemented by management fees on committed capital and carried interest from portfolio returns.

formic.vc
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Formic Ventures is a diversified venture capital firm that makes seed-stage equity investments in early-stage biotechnology startups focused on human longevity and in technology startups that reinvent how people do things. The firm also operates a philanthropic Foundation arm that makes small gifts to 501(c)(3) organizations conducting human longevity-centered research.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Formic Ventures is a diversified venture capital firm that makes seed stage investments in biotechnology startups focused on human longevity and technology startups that make human lives more meaningful. The firm operates three main investment areas: seed stage investments in early stage high potential startups that reinvent the way people do things, biotech investments in startups contributing to human longevity and making lives more meaningful, and a Foundation that makes small gifts to 501(c)(3) organizations performing human longevity-centered research. The firm does not develop or offer a standalone product; rather, its offering is its investment capital, strategic guidance, and network for portfolio companies in the biotech and technology sectors.

Product and service3 records
1Seed Stage Investments
CategoryVenture Capital Investing
Description

Equity investments in early-stage, high-potential technology and biotech startups that reinvent the way people do things, intended for founding teams raising initial capital.

2Biotech Longevity Investments
CategoryVenture Capital Investing
Description

Equity investments in biotechnology startups contributing to human longevity, including portfolio companies such as Insilico Medicine, Schrodinger, Turn Bio, and Arctoris.

3The Michael Antonov Foundation Grants
CategoryPhilanthropic Grants
Description

Small gifts to 501(c)(3) organizations performing human longevity-centered research, administered through The Michael Antonov Foundation charitable organization.

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-19
Description

Formic Ventures invested in Arctoris, a robotic-powered lab platform for biotech companies. Arctoris offers fully automated R&D capabilities that improve experiment quality, speed, and reproducibility. The platform allows scientists to focus on creative tasks while machines handle repetitive work with precision.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dedicated early-stage fund focused on human longevity and biotech, investing alongside Formic Ventures in similar anti-aging and healthspan-extension startups such as Insilico Medicine. Directly comparable thesis, stage, and target companies.

TypeDirect peer
Description

Laura Deming's seed-stage fund exclusively focused on longevity biotech. Operates at the same stage and thesis as Formic Ventures, often as co-investor or competitor in longevity rounds.

TypeDirect peer
Description

German-based longevity-focused seed fund backing rejuvenation biotech startups (e.g., Turn Bio, AgeX). Same anti-aging thesis and seed-stage approach as Formic Ventures with overlapping portfolio names.

TypeDirect peer
Description

Early-stage venture fund exclusively focused on aging and longevity research, often co-investing alongside Formic Ventures in cellular reprogramming and geroscience companies.

TypeBroad incumbent
Description

Founder-led (Peter Thiel) tech and science VC that shares Formic's founder-driven model and frontier-tech/life-sciences thesis. Has invested in Anduril and similar deep-tech names and competes for the same founder profile.

TypeDirect peer
Description

Specialized longevity biotech investor backing tissue engineering, organ preservation, and anti-aging research — overlapping thesis with Formic's longevity portfolio and stage focus.

TypeBroad incumbent
Description

Large generalist VC with a strong biotech and frontier-tech practice that often competes with Formic for AI/biotech founders; much larger AUM and institutional scale.

TypeBroad incumbent
Description

Premier biotech-focused VC that backs deep-science platform companies (including longevity-adjacent names). Comparable on biotech diligence but operates at much larger check sizes and institutional scale.

TypeBroad incumbent
Description

Biotech creation and venture firm that originates and funds platform biotech companies in health and longevity. Overlaps with Formic on biotech R&D but operates as a company-builder with significantly more capital and infrastructure.

10Y Combinator
TypeBroad incumbent
Description

Largest seed-stage accelerator backing frontier tech and biotech startups (including some longevity-related companies). Competes with Formic at the earliest stage and has a far broader funnel.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment40 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Formic Ventures

Venture Capitalformic.vc

Formic Ventures is a privately held, founder-financed seed-stage venture capital firm based in San Francisco that invests in biotechnology startups focused on human longevity and in technology startups across AI, robotics, and frontier sectors. It was founded by Oculus co-founder Michael Antonov and operates with a small specialized team.

What Formic Ventures does

Formic Ventures is a privately held, founder-financed venture capital firm based in San Francisco, California. Founded by Michael Antonov — co-founder and former Chief Software Architect of Oculus (acquired by Facebook in 2014) and co-founder of Scaleform (sold to Autodesk) — the firm makes seed-stage and early-stage equity investments in two principal verticals: biotechnology startups focused on human longevity and healthspan extension, and technology startups positioned as high-potential platforms in AI, robotics, and adjacent frontier sectors.

The firm's investment offering is its capital allocation, strategic guidance, and the network access of its small team. The internal team comprises Michael Antonov (Founder), Matt Shlosberg (Chief of Staff), Hayk Danielyan (Portfolio Manager, CFA Charterholder), and Maria Konovalenko (Scientist in Residence, PhD in Biology of Aging from the University of Southern California). Notable portfolio companies include Insilico Medicine, Schrodinger, Turn Bio, Anduril, Arctoris, Bolt, Zero, BEV, Iron Ox, and Volumetric, collectively numbering over 40 investments across biotech, AI, robotics, longevity, and consumer verticals.

Formic Ventures generates returns through equity appreciation in portfolio company exits (IPOs and acquisitions) and, where applicable, management fees and carried interest on committed capital. The firm is not disclosed to have institutional LP backing and operates as an independent, founder-owned investment vehicle. It is supported by an affiliated nonprofit, The Michael Antonov Foundation, which makes grants to 501(c)(3) organizations conducting human longevity-centered research. Co-investor relationships are maintained with LVF, Gigafund, and Anorak.

Formic Ventures firmographics

Firmographics
Name
Formic Ventures
Legal name
Formic Ventures
Website
https://formic.vc
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Formic Ventures is a privately held, founder-financed seed-stage venture capital firm based in San Francisco that invests in biotechnology startups focused on human longevity and in technology startups across AI, robotics, and frontier sectors. It was founded by Oculus co-founder Michael Antonov and operates with a small specialized team.
Ownership category
akta.pro rank

Formic Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Other Investment Pools and Funds (5259), Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAH
Venture Studios / Company Builders

Keywords

  • Venture capital investing
  • Seed stage investments
  • Biotechnology investments
  • Longevity research funding
  • Early-stage tech investments

Where Formic Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Formic Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Revenue model

  1. Venture Capital Returns: Formic Ventures generates returns through equity investments in early-stage startups. As a VC firm, the primary revenue stream comes from capital gains on successful portfolio company exits via IPOs or acquisitions, supplemented by management fees on committed capital and carried interest from portfolio returns.

Marketing channels3 records

Formic Ventures product offering

Product offering

Core offering

Formic Ventures is a diversified venture capital firm that makes seed-stage equity investments in early-stage biotechnology startups focused on human longevity and in technology startups that reinvent how people do things. The firm also operates a philanthropic Foundation arm that makes small gifts to 501(c)(3) organizations conducting human longevity-centered research.

Product overview

Formic Ventures is a diversified venture capital firm that makes seed stage investments in biotechnology startups focused on human longevity and technology startups that make human lives more meaningful. The firm operates three main investment areas: seed stage investments in early stage high potential startups that reinvent the way people do things, biotech investments in startups contributing to human longevity and making lives more meaningful, and a Foundation that makes small gifts to 501(c)(3) organizations performing human longevity-centered research. The firm does not develop or offer a standalone product; rather, its offering is its investment capital, strategic guidance, and network for portfolio companies in the biotech and technology sectors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seed Stage Investments Equity investments in early-stage, high-potential technology and biotech startups that reinvent the way people do things, intended for founding teams raising initial capital.
  • Biotech Longevity Investments Equity investments in biotechnology startups contributing to human longevity, including portfolio companies such as Insilico Medicine, Schrodinger, Turn Bio, and Arctoris.
  • The Michael Antonov Foundation Grants Small gifts to 501(c)(3) organizations performing human longevity-centered research, administered through The Michael Antonov Foundation charitable organization.

Companies that use Formic Ventures

Customer profile

Segments2 records

Ideal customer profiles2 records

Formic Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Formic Ventures partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ArctoriscoreStrategic or Co-development Partner · 19 November 2020Formic Ventures invested in Arctoris, a robotic-powered lab platform for biotech companies. Arctoris offers fully automated R&D capabilities that improve experiment quality, speed, and reproducibility. The platform allows scientists to focus on creative tasks while machines handle repetitive work with precision.

Recent moves4 records

Expansion highlights4 records

Formic Ventures competitors and assessment

Company assessment

Direct peers

  • Longevity Vision Fund: Dedicated early-stage fund focused on human longevity and biotech, investing alongside Formic Ventures in similar anti-aging and healthspan-extension startups such as Insilico Medicine. Directly comparable thesis, stage, and target companies.
  • The Longevity Fund: Laura Deming's seed-stage fund exclusively focused on longevity biotech. Operates at the same stage and thesis as Formic Ventures, often as co-investor or competitor in longevity rounds.
  • Kizoo Technology Ventures: German-based longevity-focused seed fund backing rejuvenation biotech startups (e.g., Turn Bio, AgeX). Same anti-aging thesis and seed-stage approach as Formic Ventures with overlapping portfolio names.
  • Apollo Ventures: Early-stage venture fund exclusively focused on aging and longevity research, often co-investing alongside Formic Ventures in cellular reprogramming and geroscience companies.
  • Methuselah Fund: Specialized longevity biotech investor backing tissue engineering, organ preservation, and anti-aging research — overlapping thesis with Formic's longevity portfolio and stage focus.

Broad incumbents

  • Founders Fund: Founder-led (Peter Thiel) tech and science VC that shares Formic's founder-driven model and frontier-tech/life-sciences thesis. Has invested in Anduril and similar deep-tech names and competes for the same founder profile.
  • Khosla Ventures: Large generalist VC with a strong biotech and frontier-tech practice that often competes with Formic for AI/biotech founders; much larger AUM and institutional scale.
  • ARCH Venture Partners: Premier biotech-focused VC that backs deep-science platform companies (including longevity-adjacent names). Comparable on biotech diligence but operates at much larger check sizes and institutional scale.
  • Flagship Pioneering: Biotech creation and venture firm that originates and funds platform biotech companies in health and longevity. Overlaps with Formic on biotech R&D but operates as a company-builder with significantly more capital and infrastructure.
  • Y Combinator: Largest seed-stage accelerator backing frontier tech and biotech startups (including some longevity-related companies). Competes with Formic at the earliest stage and has a far broader funnel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights6 records

Customer concentration

Formic Ventures social profiles

Digital presence

Formic Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Formic Ventures leadership team

Management profile

Number of profiles

Profiles4 records

Formic Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Formic Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Formic Ventures M&A and investment

M&A and investment

M&A

Investments40 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Formic Ventures

What does Formic Ventures do?

Formic Ventures is a diversified venture capital firm that makes seed-stage equity investments in early-stage biotechnology startups focused on human longevity and in technology startups that reinvent how people do things. The firm also operates a philanthropic Foundation arm that makes small gifts to 501(c)(3) organizations conducting human longevity-centered research.

Is Formic Ventures a public or private company?

Formic Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Formic Ventures founded?

Formic Ventures was founded in 2018. It employs 1 to 10 people.

Where is Formic Ventures based?

Formic Ventures is headquartered in San Francisco, United States, in the North America region.

How does Formic Ventures make money?

One revenue line is on record: venture Capital Returns.

Who are Formic Ventures's main competitors?

Direct peers on record are Longevity Vision Fund, The Longevity Fund, Kizoo Technology Ventures, Apollo Ventures and Methuselah Fund. Broad incumbents are Founders Fund, Khosla Ventures, ARCH Venture Partners, Flagship Pioneering and Y Combinator.

Does Formic Ventures have an API?

No public API is recorded for Formic Ventures.

What industry is Formic Ventures in?

Formic Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAH, Venture Studios / Company Builders. Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogXcellbio Announces $27.5 Million Series B FinancingXcellbio announced $27.5 million in Series B financing led by Casdin Capital, with participation from Dynamk Capital, Formic Ventures, and Labcorp. Proceeds will support growth and advance its KALI Cell Foundry platform for cell and gene therapy manufacturing. The company's AVATAR systems are deployed in over 130 labs.PR NewswireTurn Biotechnologies schließt jüngste Finanzierungsrunde abTurn Biotechnologies, a Mountain View, California-based preclinical-stage company developing RNA-based therapeutics for age-related diseases, announced the completion of its latest funding round with investments from Khosla Ventures, Shanda Group, and Formic Ventures. The new investors join the company's early investors Methuselah Fund and Methuselah Foundation, which specialize in longevity-focused companies. The funding will support the advancement of Turn's proprietary mRNA platform technology ERA™, derived from Stanford University research, targeting conditions in dermatology, ophthalmology, osteoarthritic, and muscular indications.PR NewswireTurn Biotechnologies completa su más reciente ronda de financiamientoTurn Biotechnologies, Inc. announced the closing of its latest funding round, with Khosla Ventures joining as the newest investor alongside existing investors Shanda Group and Formic Ventures. The company, which is developing mRNA-based therapies targeting age-related diseases using its ERA™ platform, also counts Methuselah Fund and Methuselah Foundation among its early backers. The funding will support the preclinical-stage company's efforts to develop treatments for dermatological, osteoarthritic, ophthalmological, and muscular conditions through epigenetic reprogramming technology originating from Stanford University.socaltech.comNanome Picks Up $3MNanome, a San Diego-based VR startup for molecular research, raised $3M in a funding round led by Bullpen Capital and Formic Ventures. The company's VR tools let researchers interact with molecular structures using goggles and controllers.